Healthcare / BiotechnologyNasdaqCM
$1.77
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-6.0M · quality 65.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-98.9%
↓Gross Margin
31.4%
↓Debt/Equity
0.34
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-8.3%
FCF CAGR
—
FCF margin
-1081.6%
FCF / Net income
0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $590084.0 · net income $-7.7M · FCF $-6.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $590084.00 | $590084.00 | — | — | $766277.00 |
| Net Income | $-7.7M | $-7.7M | $-6.2M | $-4.3M | $-1.8M |
| EBITDA | $-7.4M | $-7.4M | $-3.3M | $-1.6M | $-1.8M |
| EPS | -380.99 | -380.99 | -1195.13 | -29262.02 | -12246.72 |
| Gross Margin | 31.4% | 31.4% | — | — | 58.4% |
| Operating Margin | -1156.0% | -1156.0% | — | — | -233.4% |
| Net Margin | -1313.0% | -1313.0% | — | — | -234.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.34 | 0.34 | — | 0.05 | 0.25 |
| Current Ratio | 1.45 | 1.45 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.4M | $-6.4M | $-6.0M | $-4.6M | $-1.6M |
| Returns | |||||
| ROE | -98.9% | -98.9% | -93.8% | -112.4% | -159.1% |
| Valuation | |||||
| P/B | 0.00 | 0.00 | 1.15 | 7.52 | — |
| Growth & Yield | |||||
| EPS Growth | 68.1% | 68.1% | 95.9% | -138.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-99.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-1195.13 → -380.99
Residual
-99.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.